青少年首发精神病抗精神病药与心理干预及联合治疗可行性试验
MAPS是一项多中心、单盲、三臂随机对照的预试验与可行性研究,纳入61名14-18岁首发精神病青少年,比较抗精神病药单用、心理干预单用及两者联合的可行性。研究显示招募率为目标样本量的68%,6个月保留率84%,心理干预依从率82%,抗精神病药依从率65%;结论认为三臂头对头试验在青少年首发精神病中安全可行,但更大规模试验的可行性因中心特异性招募困难而不明确。
要点
- 三臂头对头设计在青少年首发精神病中安全可行,6个月保留率84%。
- 心理干预依从率82%,抗精神病药依从率65%,后者为中等水平。
核心结论
- 该试验首次表明在青少年首发精神病中开展心理干预、抗精神病药及联合治疗的头对头临床试验是安全的。
- 由于中心特异性招募困难,开展更大规模试验的可行性尚不明确,需修改试验设计才能进行有足够把握度的临床与成本效果试验。
研究设计与样本
- 多中心、随机、单盲、三臂对照的预试验与可行性研究,从英国7个NHS信托站点招募参与者。
- 纳入14-18岁、过去一年内首发精神病、当前有精神病性症状、符合ICD-10精神分裂症/分裂情感性障碍/妄想障碍或早期干预服务准入标准者。
- 参与者按1:1:1随机分配至抗精神病药、心理干预(CBT可选家庭干预)或抗精神病药联合心理干预,随访最长12个月。
- CBT最多26次会话持续6个月加最多4次强化会话,家庭干预最多6次会话持续6个月;抗精神病药选择与剂量由治疗顾问精神科医生决定。
- 主要结局为可行性指标, proposed主要疗效结局为6个月PANSS总分;可行性按意向治疗分析,安全性按实际治疗状态报告。
主要发现
- 招募率为目标样本量90人的68%,转介至招募比约2:1,6个月主要终点保留51人(84%)。
- 心理干预依从(定义为CBT≥6次)在单药与联合组39人中达32人(82%),抗精神病药依从(定义为连续暴露≥6周)在43人中达28人(65%)。
- 6个月良好临床反应(PANSS总分改善≥50%)在抗精神病药单用组18人中4人(22%)、心理干预组16人中5人(31%)、联合组17人中5人(29%)中达成。
关键数值与推荐
- 可行性主要结局包括试验转介与招募数据、会话出席或药物依从、保留率及治疗可接受性。
- 心理干预依从定义为6次或以上CBT会话;抗精神病药依从定义为至少连续6周暴露于抗精神病药。
- 良好临床反应定义为6个月PANSS总分改善≥50%。
- 安全性按实际治疗状态报告,严重不良事件在联合组23人中8人(35%)、抗精神病药组15人中2人(13%)、心理干预组17人中4人(24%)、未接受任何治疗5人中4人(80%)发生;无严重不良事件被认为与试验参与相关。
临床怎么用
- 结果支持在青少年首发精神病中可安全开展抗精神病药、心理干预及联合治疗的随机对照试验。
- 心理干预依从性高而抗精神病药依从性中等,提示临床需关注药物依从性支持。
- 三组6个月PANSS总分均较随机化时下降,心理干预与联合治疗降幅数值上大于抗精神病药单用,但研究为可行性试验,不能据此得出疗效优劣结论。
局限性
- 该研究为预试验与可行性研究,样本量小(61人),未按疗效检验设计把握度。
- 招募未达目标样本量(68%),存在中心特异性招募困难,影响更大规模试验的可行性判断。
- 抗精神病药选择与剂量由治疗医生决定,非标准化干预可能影响结果解释。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Evidence for the effectiveness of treatments in early-onset psychosis is sparse. Current guidance for the treatment of early-onset psychosis is mostly extrapolated from trials in adult populations. The UK National Institute for Health and Care Excellence has recommended evaluation of the clinical effectiveness and cost-effectiveness of antipsychotic drugs versus psychological intervention (cognitive behavioural therapy [CBT] and family intervention) versus the combination of these treatments for early-onset psychosis. The aim of this study was to establish the feasibility of a randomised controlled trial of antipsychotic monotherapy, psychological intervention monotherapy, and antipsychotics plus psychological intervention in adolescents with first-episode psychosis. METHODS: We did a multicentre pilot and feasibility trial according to a randomised, single-blind, three-arm, controlled design. We recruited participants from seven UK National Health Service Trust sites. Participants were aged 14-18 years; help-seeking; had presented with first-episode psychosis in the past year; were under the care of a psychiatrist; were showing current psychotic symptoms; and met ICD-10 criteria for schizophrenia, schizoaffective disorder, or delusional disorder, or met the entry criteria for an early intervention for psychosis service. Participants were assigned (1:1:1) to antipsychotics, psychological intervention (CBT with optional family intervention), or antipsychotics plus psychological intervention. Randomisation was via a web-based randomisation system, with permuted blocks of random size, stratified by centre and family contact. CBT incorporated up to 26 sessions over 6 months plus up to four booster sessions, and family intervention incorporated up to six sessions over 6 months. Choice and dose of antipsychotic were at the discretion of the treating consultant psychiatrist. Participants were followed up for a maximum of 12 months. The primary outcome was feasibility (ie, data on trial referral and recruitment, session attendance or medication adherence, retention, and treatment acceptability) and the proposed primary efficacy outcome was total score on the Positive and Negative Syndrome Scale (PANSS) at 6 months. Primary outcomes were analysed by intention to treat. Safety outcomes were reported according to as-treated status, for all patients who had received at least one session of CBT or family intervention, or at least one dose of antipsychotics. The study was prospectively registered with ISRCTN, ISRCTN80567433. FINDINGS: Of 101 patients referred to the study, 61 patients (mean age 16·3 years [SD 1·3]) were recruited from April 10, 2017, to Oct 31, 2018, 18 of whom were randomly assigned to psychological intervention, 22 to antipsychotics, and 21 to antipsychotics plus psychological intervention. The trial recruitment rate was 68% of our target sample size of 90 participants. The study had a low referral to recruitment ratio (around 2:1), a high rate of retention (51 [84%] participants retained at the 6-month primary endpoint), a high rate of adherence to psychological intervention (defined as six or more sessions of CBT; in 32 [82%] of 39 participants in the monotherapy and combined groups), and a moderate rate of adherence to antipsychotic medication (defined as at least 6 consecutive weeks of exposure to antipsychotics; in 28 [65%] of 43 participants in the monotherapy and combined groups). Mean scores for PANSS total at the 6-month primary endpoint were 68·6 (SD 17·3) for antipsychotic monotherapy (6·2 points lower than at randomisation), 59·8 (13·7) for psychological intervention (13·1 points lower than at randomisation), and 62·0 (15·9) for antipsychotics plus psychological intervention (13·9 points lower than at randomisation). A good clinical response at 6 months (defined as ≥50% improvement in PANSS total score) was achieved in four (22%) of 18 patients receiving antipsychotic monotherapy, five (31%) of 16 receiving psychological intervention, and five (29%) of 17 receiving antipsychotics plus psychological intervention. In as-treated groups, serious adverse events occurred in eight [35%] of 23 patients in the combined group, two [13%] of 15 in the antipsychotics group, four [24%] of 17 in the psychological intervention group, and four [80%] of five who did not receive any treatment. No serious adverse events were considered to be related to participation in the trial. INTERPRETATION: This trial is the first to show that a head-to-head clinical trial comparing psychological intervention, antipsychotics, and their combination is safe in young people with first-episode psychosis. However, the feasibility of a larger trial is unclear because of site-specific recruitment challenges, and amendments to trial design would be needed for an adequately powered clinical and cost-effectiveness trial that provides robust evidence. FUNDING: National Institute for Health Research.
引用
- Morrison AP, Pyle M, Maughan D, et al. Antipsychotic medication versus psychological intervention versus a combination of both in adolescents with first-episode psychosis (MAPS): a multicentre, three-arm, randomised controlled pilot and feasibility study. Lancet Psychiatry. 2020. PMID: 32649925. doi:10.1016/S2215-0366(20)30248-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。